Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Minority Interest (2019 - 2025)

Historic Minority Interest for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to -$191000.0.

  • aTYR PHARMA's Minority Interest fell 268.82% to -$191000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$191000.0, marking a year-over-year decrease of 268.82%. This contributed to the annual value of -$187000.0 for FY2024, which is 53.19% up from last year.
  • aTYR PHARMA's Minority Interest amounted to -$191000.0 in Q3 2025, which was down 268.82% from -$189000.0 recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Minority Interest ranged from a high of -$170000.0 in Q1 2021 and a low of -$191000.0 during Q3 2025
  • Over the past 5 years, aTYR PHARMA's median Minority Interest value was -$184000.0 (recorded in 2024), while the average stood at -$181578.9.
  • In the last 5 years, aTYR PHARMA's Minority Interest crashed by 613.5% in 2021 and then soared by 54.05% in 2024.
  • aTYR PHARMA's Minority Interest (Quarter) stood at -$175000.0 in 2021, then decreased by 2.86% to -$180000.0 in 2022, then fell by 4.44% to -$188000.0 in 2023, then rose by 0.53% to -$187000.0 in 2024, then fell by 2.14% to -$191000.0 in 2025.
  • Its Minority Interest was -$191000.0 in Q3 2025, compared to -$189000.0 in Q2 2025 and -$188000.0 in Q1 2025.